American Century Companies Portfolio holdings
American Century Companies, Inc., founded in 1958 by James E. Stowers Jr. as Twentieth Century Mutual Funds and headquartered in Kansas City, Missouri, is a privately held investment management firm renowned for its focus on delivering investment results to clients while supporting medical research. Starting with just $100,000 from 24 shareholders, it rebranded to American Century Investments in 1997 and now manages hundreds of billions in assets across mutual funds, ETFs, and institutional portfolios, emphasizing no-load funds and a client-centric approach. The firm’s unique ownership structure sees over 40% of its profits funneled to the Stowers Institute for Medical Research, which it majority-owns, funding groundbreaking biomedical research, while Nomura Holdings holds a significant minority stake. With a global presence in cities like New York, London, and Hong Kong, and a workforce of around 1,400, American Century blends financial expertise with a mission to improve lives through both wealth creation and scientific advancement.
Top Buys
| 1 |
Broadcom
AVGO
|
+$701M |
| 2 |
Mastercard
MA
|
+$306M |
| 3 |
Estee Lauder
EL
|
+$248M |
| 4 |
IQVIA
IQV
|
+$178M |
| 5 |
Arista Networks
ANET
|
+$163M |
Top Sells
| 1 |
Visa
V
|
+$560M |
| 2 |
Advanced Micro Devices
AMD
|
+$524M |
| 3 |
Apple
AAPL
|
+$439M |
| 4 |
NVIDIA
NVDA
|
+$318M |
| 5 |
iShares Russell 1000 Growth ETF
IWF
|
+$261M |
Sector Composition
| 1 | Technology | 27.32% |
| 2 | Financials | 13.83% |
| 3 | Consumer Discretionary | 12.65% |
| 4 | Healthcare | 10.02% |
| 5 | Industrials | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2676
loanDepot
LDI
$894M
| $245K | ﹤0.01% |
120,232
+13,628
| +13% | +$27.8K |
|
2677
Advanced Energy
AEIS
$5.94B
| $245K | ﹤0.01% |
+2,118
| New | +$245K |
|
|
BRSL
2678
Brightstar Lottery PLC
BRSL
$3.12B
| $243K | ﹤0.01% |
13,766
-9,158
| -40% | -$162K |
|
2679
Design Therapeutics
DSGN
$343M
| $241K | ﹤0.01% |
39,115
+6,481
| +20% | +$40K |
|
2680
ProQR Therapeutics
PRQR
$231M
| $237K | ﹤0.01% |
+89,527
| New | +$237K |
|
2681
Pulmonx
LUNG
$69.3M
| $236K | ﹤0.01% |
34,738
+2,810
| +9% | +$19.1K |
|
2682
Evolv Technologies
EVLV
$1.51B
| $236K | ﹤0.01% |
59,682
+24,527
| +70% | +$96.9K |
|
2683
Corvus Pharmaceuticals
CRVS
$434M
| $234K | ﹤0.01% |
43,774
+25,566
| +140% | +$137K |
|
2684
Cardiff Oncology
CRDF
$136M
| $234K | ﹤0.01% |
53,955
+6,140
| +13% | +$26.6K |
|
2685
Park Hotels & Resorts
PK
$2.39B
| $233K | ﹤0.01% |
16,532
+1,816
| +12% | +$25.6K |
|
|
NNDM
2686
Nano Dimension
NNDM
$309M
| $232K | ﹤0.01% |
93,674
+214
| +0.2% | +$531 |
|
2687
Summit Therapeutics
SMMT
$14.1B
| $231K | ﹤0.01% |
+12,971
| New | +$231K |
|
2688
Expensify
EXFY
$178M
| $229K | ﹤0.01% |
68,228
+27,541
| +68% | +$92.3K |
|
2689
Liberty Media Series A
FWONA
$22.5B
| $228K | ﹤0.01% |
+2,714
| New | +$228K |
|
2690
Sotera Health
SHC
$4.56B
| $228K | ﹤0.01% |
16,656
| – | – |
|
2691
Liberty Broadband Class A
LBRDA
$8.65B
| $227K | ﹤0.01% |
3,053
+296
| +11% | +$22K |
|
2692
Nkarta
NKTX
$140M
| $226K | ﹤0.01% |
90,952
+7,378
| +9% | +$18.4K |
|
2693
Enviri
NVRI
$983M
| $226K | ﹤0.01% |
29,391
+8,865
| +43% | +$68.3K |
|
2694
Liberty Live Group Series A
LLYVA
$8.95B
| $225K | ﹤0.01% |
+3,381
| New | +$225K |
|
2695
Amylyx Pharmaceuticals
AMLX
$1.24B
| $224K | ﹤0.01% |
59,310
+38,261
| +182% | +$145K |
|
2696
Bausch Health
BHC
$2.68B
| $220K | ﹤0.01% |
27,236
+2,600
| +11% | +$21K |
|
|
INZY
2697
DELISTED
Inozyme Pharma
INZY
| $220K | ﹤0.01% |
79,349
+8,263
| +12% | +$22.9K |
|
2698
Larimar Therapeutics
LRMR
$336M
| $218K | ﹤0.01% |
56,294
+13,891
| +33% | +$53.8K |
|
2699
Clearway Energy Class A
CWEN.A
$3.21B
| $217K | ﹤0.01% |
8,886
-35
| -0.4% | -$856 |
|
2700
4D Molecular Therapeutics
FDMT
$318M
| $216K | ﹤0.01% |
38,785
+4,429
| +13% | +$24.7K |
|